Sagimet Biosciences (SGMT) Cash from Operations (2022 - 2026)
Sagimet Biosciences (SGMT) posted quarterly Cash from Operations of 8611000.0 for Q1 2026, up 40.76% year-over-year from 6117467.18 in Q1 2025, and up 27.23% quarter-over-quarter from 11833000.0 in Q4 2025.
Sagimet Biosciences (SGMT) Cash from Operations (2022 - 2026) Analysis & Trends
Sagimet Biosciences' Cash from Operations history runs 5 years deep, the most recent figure standing at 8611000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 40.76% year-over-year to 8611000.0; the TTM figure through Mar 2026 stood at 39725000.0 (up 21.74% YoY), while the FY2025 annual figure was 45650000.0, down 7.58% from the prior year.
- Cash from Operations for Q1 2026 stood at 8611000.0, up from 11833000.0 in the prior quarter.
- The five-year high for Cash from Operations was 3000.0 in Q2 2022, with the low at 19569000.0 in Q3 2024.
- The 5-year median for Cash from Operations is 7268500.0 (2022), against an average of 8384500.0.
- The sharpest annual moves came in 2023 and 2025: Cash from Operations sank 190566.67% in 2023, then jumped 47.98% in 2025.
- Sagimet Biosciences' Cash from Operations stood at 7453000.0 in 2022, then advanced by 4.96% to 7083000.0 in 2023, then slumped by 55.64% to 11024000.0 in 2024, then fell by 7.34% to 11833000.0 in 2025, then rose by 27.23% to 8611000.0 in 2026.
- Business Quant data shows SGMT's Cash from Operations at 8611000.0 in Q1 2026, 11833000.0 in Q4 2025, and 10180000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Sagimet Biosciences | 649.79 Mn | 649.79 Mn | - | -11.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.10 Mn |
| Jun 30, 2026 | -11.10 Mn |
| Mar 31, 2026 | -8.61 Mn |
| Mar 31, 2026 | -8.61 Mn |
| Dec 31, 2025 | -11.83 Mn |
| Dec 31, 2025 | -11.83 Mn |
| Sep 30, 2025 | -10.18 Mn |
| Sep 30, 2025 | -10.18 Mn |
| Jun 30, 2025 | -9.10 Mn |
| Jun 30, 2025 | -9.10 Mn |
| Mar 31, 2025 | -14.54 Mn |
| Mar 31, 2025 | -14.54 Mn |
| Dec 31, 2024 | -11.02 Mn |
| Dec 31, 2024 | -11.02 Mn |
| Sep 30, 2024 | -19.57 Mn |
| Sep 30, 2024 | -19.57 Mn |
| Jun 30, 2024 | -5.63 Mn |
| Jun 30, 2024 | -5.63 Mn |
| Mar 31, 2024 | -6.21 Mn |
| Mar 31, 2024 | -6.21 Mn |